Richards Bay

Researchers are evaluating the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo plus CDK46i and letrozole in adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive HR, HER2-negative advanced breast cancer. This phase III, randomized, double-blind study focuses on participants who have measurable disease and meet specific hormone receptor and HER2 status criteria. Participants are randomly assigned to receive either oral inavolisib once daily along with letrozole and CDK46i or placebo once daily with letrozole and CDK46i. The CDK46i is given on a schedule of either Days 1-21 or Days 1-28 of each 28-day cycle. The study includes parallel groups to compare these treatment combinations over time. During the study, participants will be monitored for progression-free survival, overall survival, response rates, duration of response, clinical benefit, and changes in pain, physical function, and global health status. Safety will be assessed by tracking adverse events and patient-reported treatment side effects using questionnaires. The study will follow participants for up to seven years, with regular evaluations to track disease status and quality of life.

This research aims to evaluate the safety and effectiveness of EIK1001 combined with Pembrolizumab compared to placebo plus Pembrolizumab as a first treatment in patients with advanced melanoma. The study is a multicenter, randomized, double-blind, active comparator-controlled, adaptive Phase 23 trial including dose optimization and expansion parts. Participants must have advanced melanoma eligible for standard pembrolizumab therapy. Participants are assigned randomly to one of three groups placebo with Pembrolizumab, EIK1001 at dose 1 plus Pembrolizumab, or EIK1001 at dose 2 plus Pembrolizumab. EIK1001 is a dual agonist targeting Toll-like receptor 78, and Pembrolizumab is a PD-1 inhibitor. The study includes dose optimization and expansion phases to assess the treatments as first-line therapies. During the trial, participants will undergo regular assessments including imaging by CT or MRI to measure tumor response using RECIST 1.1 criteria. Safety is monitored through reports of adverse events and laboratory tests. The primary outcomes include progression-free survival and overall survival monitored up to 5 years, with additional evaluation of response duration and adverse events. Participation involves ongoing treatment and follow-up visits throughout the study period.